Navigation Links
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Date:10/1/2008

ore as fat by mimicking the effects of naturally occurring hormones. Amylin's approach has the potential to achieve significant weight loss with a reduced risk for side effects that are often seen with other obesity treatments."

KEY AMYLIN ACTIVITIES AT THE OBESITY SOCIETY MEETING

1. Invited symposium presentation: "Therapeutic Potential of Leptin in

General Obesity: A New, Integrated Neurohormonal Approach" will be

presented by Christian Weyer, MD, Vice President, Corporate

Development for Diabetes and Obesity at Amylin Pharmaceuticals, Inc.,

as part of a symposium entitled "Leptin: From Bench to Bedside" on

Sunday, October 5 from 3:45-5:30 p.m. PT (6:45 p.m. ET). This

symposium is part of the conference's core scientific program.

2. Oral 64-OR: "Enhanced weight loss following pramlintide/metreleptin

combination treatment in overweight and obese subjects is accompanied

by improved control of eating" will be presented by Steve Smith, MD,

Sunday, October 5 at 11:45 a.m. PT (2:45 p.m. ET).

3. Poster 323-P: "Safety of 360 ug pramlintide BID treatment for up to 2

years" will be presented by Nicole Kesty, PhD, Saturday, October 4 at

5 p.m. PT (8 p.m. ET).

4. Poster 592-P: "Changes in weight and binge eating scale scores in

obese subjects treated with pramlintide as monotherapy and in

combination with oral weight loss agents" will be presented by Fulton

Velez, MD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).

5. Poster 205-P: "Effects of amylin/leptin lead-in on the weight-reducing

effects of amylin and/or leptin in diet-induced obese (DIO) rats" will

be presented by Chunli Lei, Saturday, October 4 at 5 p.m. PT

(8 p.m. ET).

6. Poster 651-P: "AC2307, an amylin mimetic, reduced 24-h food intake in

obese subjects without changing sub
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Critical Pharmaceuticals Enter Sustained Release hGH Arena
4. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
5. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)... 2008 Faces of Influenza survey underscores that m...uenza; Mother and Gold Medalist Kristi Yamaguchi j...RNewswire/ -- While 78 percent of mothers in the U...tially life-threatening disease that can strike an...ll get vaccinated this season, according to a new ...
(Date:11/13/2008)...itional Supplements Prior to Surgery, ARLINGTON H...dentifying,malnutrition before surgery in massive ...significantly decrease surgical complications, acc...ost patient energy levels,according to a study in...Surgery(R), the official medical journal of the Am...
(Date:11/12/2008)...h James D. Watson, Marilyn & James Simons and,Sher..., Md., Nov. 12 J. Craig...aig Venter Institute (JCVI), was,awarded the Doubl...CSHL) on,November 6th at a gala event in New York ... along with Dr. James D.,Watson for making each of...
(Date:11/12/2008)... Study and New Data Suggesting Need for Improved ...l Meeting -, EXTON, Pa., Nov. 12 /PRNewswire-Firs... today announced the presentation of data from its...tudy Cinryze(TM) C1 inhibitor,therapy successfully...(HAE),attacks seen in the study through the date o...
Breaking Medicine Technology:Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 2ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 3ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 4ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 5ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema 6Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 1Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 2Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 3Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 4Raptor Pharmaceuticals Corp Initiates Phase IIa Clinical Study for Convivia 28TM 29 1856 55th Annual World Health Care Congress Kicks off April 21 With Obama Clinton McCain Health Care Policy Advisor Presidential Health Care Agenda Forum 17263 15th Annual World Health Care Congress Kicks off April 21 With Obama Clinton McCain Health Care Policy Advisor Presidential Health Care Agenda Forum 17263 2 C O R R E C T I O N Mobidiag Ltd 4718 1 C O R R E C T I O N Mobidiag Ltd 4718 2Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 1Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 2Vernalis and Paul Capital Healthcare Sign euro 18 4 Million Financing Agreement 4717 3
(Date:11/21/2008)... Calif., Nov. 21 Album Creative St...launches a new program offering big brand marketin...the large, expensive ad agency process and service...ry hands-on approach," says Matt Parker, Creative ...ines experience and proven brand-building techniqu...
(Date:11/21/2008)...E, Fla. -- A Florida State University College of M...covered an important new layer of regulation in th...er understanding of the way cancer begins. , Wan...t the College of Medicine, said the findings will ... could lead to the design of new drugs that kill c...
(Date:11/21/2008)... Nov. 21 The Providence ...nced that Craig A. Norris, the Company,s,Chief Op...,s Board of,Directors. Mr. Norris, appointment f...on of Steven I. Geringer and returns the board to ...mmittee of the Board. , Mr. Norris, age 41,...
(Date:11/21/2008)...one day lead to a novel technique to combat cancer...althDay News) -- Belgian researchers have discover...of sugar for food, and this might lead to new trea...urvive and proliferate, all cells in the body need...[glucose], a process that requires oxygen. Compare...
Breaking Medicine News(10 mins):Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2
...ugs (NSAIDs) are known to enable manifold benefits...ead carefully, evaluating potential risks before s...rding to a diverse expert panel.// Gastrointestin...of NSAID use that could mean complications in both...
...ineered mice has revealed that the dreaded white b...or transplants may also help prevent such damage//...chers have long known that when blood flow is cut ...kidneys or other organs, immune system cells calle...
...immune systems of fish and mammals in the form of ...of the immune system //has been discovered by rese... of Veterinary Medicine. Their studies link the e...in mammals, where B cells produce antibodies to fi...
...ter has become the first hospital in the region to...h doctors believe will change the standard of care...R/Cath Lab, the state-of-the-art operating suite h... devices necessary to perform open-heart surgeries...
Other Medicine News:Health News:Nonsteroidal anti-inflammatory drugs could cause gastrointestinal complications. 2Health News:Nonsteroidal anti-inflammatory drugs could cause gastrointestinal complications. 3Health News:Study Reveals Effects of WBCs on Transplanted Kidney 2Health News:Study Reveals Effects of WBCs on Transplanted Kidney 3Health News:Link between Fish and Mammal Immune Systems Revealed by Killer B cells 2Health News:Link between Fish and Mammal Immune Systems Revealed by Killer B cells 3Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 2Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 3Health News:A New Approach to Heart Bypass Surgery Provides Patients with 'One-stop Shopping' 4
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Medicine Products: